Aldevron Launches New Innovation Center in Waltham, MA

FARGO, N.D. & WALTHAM, Mass.--(BUSINESS WIRE)--Jul 30, 2025--

Aldevron, a Danaher company, and a global leader in the production of DNA, RNA and protein in the genomic medicine space, today announced the planned opening of its new Innovation Center in Waltham, Massachusetts. The milestone marks a bold step in Aldevron’s mission to accelerate innovation in genomic medicines while deepening its presence in one of the world’s most dynamic biotech hubs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730851598/en/

The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA and proteins for advanced therapies, expanding Aldevron’s capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies.

“Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery,” said Venkata Indurthi, Chief Scientific Officer at Aldevron. “This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech.”

The Waltham Innovation Center will complement Aldevron’s established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston’s vibrant biotech community.

“Our recent role in the groundbreaking ‘Baby KJ’ CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation,” said Jennifer Meade, President of Aldevron. “As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine.”

About Aldevron

Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron’s expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world’s first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe.

To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us and follow the company on LinkedIn, Facebook and YouTube.

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Aldevron Launches New Innovation Center in Waltham, MA

Aldevron Launches New Innovation Center in Waltham, MA

CARACAS, Venezuela (AP) — Venezuela’s acting President Delcy Rodríguez on Thursday asked lawmakers to approve reforms to the oil industry that would open the doors to greater foreign investment during her first state of the union speech less than two weeks after its longtime leader was toppled by the United States.

Rodríguez, who has been under pressure by the Trump administration to fall in line with its vision for the oil-rich nation, said sales of Venezuelan oil would go to bolster crisis-stricken health services, economic development and other infrastructure projects.

She outlined a distinct vision for the future, straying from her predecessors, who have long railed against American intervention in Venezeula. “Let us not be afraid of diplomacy” with the U.S., said Rodriguez, the former vice president who must now navigate competing pressures from the Trump administration and a government loyal to former President Nicolás Maduro.

The speech, which was broadcast on a delay in Venezuela, came one day after Rodríguez said her government would continue releasing prisoners detained under Maduro in what she described as “a new political moment” since his ouster.

On Thursday, Trump met at the White House with Venezuelan opposition leader María Corina Machado, whose political party is widely considered to have won 2024 elections rejected by Maduro. But in endorsing Rodríguez, who served as Maduro’s vice president since 2018, Trump has sidelined Machado.

Rodríguez, who had a call with Trump earlier this week, said Wednesday evening on state television that her government would use “every dollar” earned from oil sales to overhaul the nation’s public health care system. Hospitals and other health care facilities across the country have long been crumbling, and patients are asked to provide practically all supplies needed for their care, from syringes to surgical screws.

The acting president must walk a tightrope, balancing pressures from both Washington and top Venezuelan officials who hold sway over Venezuela's security forces and strongly oppose the U.S. Her recent public speeches reflect those tensions — vacillating from conciliatory calls for cooperation with the U.S., to defiant rants echoing the anti-imperialist rhetoric of her toppled predecessor.

American authorities have long railed against a government they describe as a “dictatorship,” while Venezuela’s government has built a powerful populist ethos sharply opposed to U.S. meddling in its affairs.

For the foreseeable future, Rodríguez's government has been effectively relieved of having to hold elections. That's because when Venezuela’s high court granted Rodríguez presidential powers on an acting basis, it cited a provision of the constitution that allows the vice president to take over for a renewable period of 90 days.

Trump enlisted Rodríguez to help secure U.S. control over Venezuela’s oil sales despite sanctioning her for human rights violations during his first term. To ensure she does his bidding, Trump threatened Rodríguez earlier this month with a “situation probably worse than Maduro.”

Maduro, who is being held in a Brooklyn jail, has pleaded not guilty to drug-trafficking charges.

Before Rodríguez’s speech on Thursday, a group of government supporters was allowed into the presidential palace, where they chanted for Maduro, who the government insists remains the country’s president. “Maduro, resist, the people are rising,” they shouted.

Follow AP’s coverage of Latin America and the Caribbean at https://apnews.com/hub/latin-america

Venezuela's acting President Delcy Rodriguez makes a statement to the press at Miraflores presidential palace in Caracas, Venezuela, Wednesday, Jan. 14, 2026. (AP Photo/Ariana Cubillos)

Venezuela's acting President Delcy Rodriguez, center, smiles flanked by Interior Minister Diosdado Cabello, right, and National Assembly President Jorge Rodriguez after making a statement to the press at Miraflores presidential palace in Caracas, Venezuela, Wednesday, Jan. 14, 2026. (AP Photo/Ariana Cubillos)